The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a ...

The active ingredient in the popular weight loss drug Wegovy may help treat a type of fatty liver disease, according to a new ...

A global trial finds Wegovy and Ozempic significantly improve liver health in patients and treats those with advanced fatty ...

Novo Nordisk (NVO) stock in focus as oral Wegovy is accepted for FDA review for chronic weight management. Read more here.

Of the total ER visits, nearly 70% involved GI issues, 15% of which led to hospitalization, according to a new study.

A decision is expected in the fourth quarter of 2025.

SHOPPING: If you're ready to meet your weight goals, turn to Hims for personalized weight loss treatments that are ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Investing.com -- Novo Nordisk (NYSE: NVO) shares climbed 5.4% Friday after the U.S. Food and Drug Administration accepted the ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...